Venture Capital

With a fresh $130M and a key acquisition, Deepgram is building the infrastructure for a future where voice AI is as seamless as human conversation.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

A new fellowship in Newfoundland and Labrador aims to solve critical gaps in anesthesiology, boosting the region's health innovation ecosystem.

New data reveals couples are ditching performative trends for authentic celebrations, prioritizing personal stories, immersive experiences, and real-time content.

The high-power laser maker exceeded its Q4 guidance, driven by booming demand in aerospace and defense. Here's what it means for its 2026 outlook.

After a breakthrough CES demo, BookAI is raising capital to scale its platform that turns static books into interactive assets, breaking language barriers.

As Lithuania's grid operator faces a new era of digital demands and renewable integration, a former telecom CTO is set to take the lead in a major strategic shift.

A new US-French partnership brings fermentation-derived algal oils to Europe, promising superior performance and a traceable alternative to plant oils.

With a new lineup including a $699 model, ZWHAND's debut at CES 2026 could accelerate the mass adoption of dexterous robots in every field.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

Sonos adds leaders from Meta, e.l.f. Beauty, and Pandora to its board, signaling a strategic push into AI, platform growth, and financial discipline.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

The AI health-tech leader achieved profitability and massive growth in 2025, expanding its reach to nearly 2,000 hospitals and doubling its life sciences arm.

The investment firm celebrated a strong 2025 with shareholder payouts, fueled by profitable exits and a new major investment in AI infrastructure firm TensorWave.

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

OpenText divests its on-premise eDOCS unit to NetDocuments, using the cash for debt reduction while sharpening its focus on AI and cloud services.

Cosmetics brand Sorevna is diving into the crowded bath and body sector, promising a revolutionary launch. But can its science-first approach succeed?

1X just unveiled a new AI model letting its NEO humanoid learn from internet videos, blurring the line between digital AI and physical reality. But is the world ready?

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

ProductPlan acquires AI-native Winware.ai, naming founder Steven Cohn its new CEO to forge an intelligence platform aimed at ending product uncertainty.